baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 01/25 IDP/ DE000UG0PUM8 /

1/3/2025 1:41:20 PM	Chg.-	Bid1/3/2025	Ask1/3/2025	Underlying	Strike price	Expiration date	Option type
0.2600EUR	-	0.2600 Bid Size: 10,000	- Ask Size: 10,000	BIOGEN INC. DL -,000...	155.00 -	1/15/2025	Call

TeleTrader 10/30/2024 Biogen's Q3 revenue down 3% to $2.5 billion

TeleTrader 8/1/2024 Biogen books $2.5 billion in Q2 revenue

GlobeNewswire 7/30/2024 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...

GlobeNewswire 7/30/2024 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...

GlobeNewswire 7/26/2024 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

GlobeNewswire 7/2/2024 Biogen Completes Acquisition of Human Immunology Biosciences

GlobeNewswire 6/28/2024 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

GlobeNewswire 6/24/2024 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

GlobeNewswire 6/10/2024 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...

GlobeNewswire 6/3/2024 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...

GlobeNewswire 5/30/2024 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...

GlobeNewswire 5/22/2024 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...

GlobeNewswire 5/21/2024 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

GlobeNewswire 5/16/2024 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...

GlobeNewswire 5/15/2024 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...

GlobeNewswire 5/2/2024 Biogen Reports Progress on Corporate Responsibility Priorities

GlobeNewswire 4/25/2024 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...

TeleTrader 4/24/2024 Biogen posts Q1 revenue of $2.3 billion

GlobeNewswire 4/23/2024 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...

GlobeNewswire 4/2/2024 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

GlobeNewswire 3/6/2024 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...

GlobeNewswire 3/4/2024 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...

GlobeNewswire 2/23/2024 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...

TeleTrader 2/13/2024 Biogen's Q4 revenue falls 6% to $2.4 billion

GlobeNewswire 2/12/2024 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...

UC WAR. CALL 01/25 IDP/ DE000UG0PUM8 /

If you wish to receive reply to your feedback, please provide your email address.